ARTICLE | Clinical News
Genzyme and Diacrin extend Phase II trial
September 14, 2000 7:00 AM UTC
GENZ and DCRN will extend their Phase II trial of NeuroCell-PD to treat Parkinson's disease from 12 months to 18 months in order to provide long term durability and efficacy data. The extension follow...